Condition: COVID-19 · Immunodeficiency · Sponsor: ANRS, Emerging Infectious Diseases
The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy DAA (remdesivir + nirmatrelvir/r)∞ versus the reference monotherapy (nirmatrelvir/r alone) and to assess the efficacy and safety of increasing the nirmatrelvir/r course from 5- to 10 days in immunocompromised patients diagnosed with asymptomatic or mild to moderate COVID-19.
This description comes directly from the study's public registry record.
Douae Ammour · +33782960531 · douae.ammour@inserm.fr
Chiara Fedeli · +41 (0)22 372 9817 · chiara.fedeli@hug.ch
Always discuss trial participation with your own doctor first.
| Saint-André Hospital | Bordeaux, Bordeaux, France | Recruiting |
| Pellegrin Hospital | Bordeaux, Bordeaux, France | Recruiting |
| Francois Mitterrand Hospital | Dijon, Dijon, France | Recruiting |
| Croix Rousse Hospital | Lyon, Lyon, France | Recruiting |
| La Colombière Hospital | Montpellier, Montpellier, France | Recruiting |
| Hotel Dieu Hospital | Nantes, Nantes, France | Recruiting |
| Laribosière Hospital | Paris, Paris, France | Recruiting |
| Saint Antoine Hospital | Paris, Paris, France | Recruiting |
| Pitié-Salpêtrière Hospital | Paris, Paris, France | Recruiting |
| Saint Louis Hospital | Paris, Paris, France | Recruiting |
| Bichat Claude-Bernard Hospital | Paris, Paris, France | Recruiting |
| Robert Debré Hospital | Reims, Reims, France | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05587894